US › Healthcare

Cellectis SA (CLLS)

US · Healthcare · Biotechnology

$1.46+6.18%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$5.2M

Revenue YoY

-68.8%

Net profit

$-21.8M

EPS

$-0.22

EPS estimate

$-0.25

Net margin

-417.3%

EPS came in at -0.22 against a street estimate of -0.25 — a beat of 12.0%.

Key statistics

Market cap

$312.2M

Forward P/E

0.0

P/B

7.65

Book value

$0.56

EPS (TTM)

$-0.64

52-week high

$5.48

52-week low

$2.35

50-day MA

$3.03

200-day MA

$3.66

Beta

2.77

Analyst view

Analysts rate Cellectis SA a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $7.60.

Shareholding

Institutions

15.36%

Largest institutional holders

Fund	Stake
B Group, Inc	3.26%
UBS Asset Mgmt Americas Inc	3.16%
Long Focus Capital Management, LLC	2.72%
BlackRock Inc	0.34%
Delaware Management Holdings Inc	0.23%
Morgan Stanley - Brokerage Accounts	0.09%
LPL Financial Corp	0.08%
Susquehanna International Group, LLP	0.07%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cellectis SA — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.